Profile data is unavailable for this security.
About the company
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
- Revenue in SEK (TTM)1.72bn
- Net income in SEK431.44m
- Incorporated2004
- Employees213.00
- LocationCamurus ABIdeongatan 1ALUND 223 62SwedenSWE
- Phone+46 462865730
- Fax+46 462865739
- Websitehttps://www.camurus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calliditas Therapeutics AB | 1.21bn | -466.18m | 6.01bn | 181.00 | -- | 16.18 | -- | 4.98 | -8.69 | -8.69 | 22.49 | 6.24 | 0.6332 | 5.02 | 8.77 | 6,667,895.00 | -24.46 | -26.46 | -30.27 | -30.27 | 94.99 | -- | -38.63 | -76.59 | 3.08 | -4.44 | 0.7427 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| Surgical Science Sweden AB | 882.85m | 233.97m | 7.52bn | 260.00 | 32.10 | 1.73 | 25.95 | 8.51 | 4.59 | 4.59 | 17.32 | 85.16 | 0.1888 | 1.87 | 6.15 | 3,395,589.00 | 5.00 | 4.49 | 5.31 | 4.78 | 69.42 | 70.06 | 26.50 | 23.75 | 3.56 | -- | -- | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
| Gubra A/S | 320.80m | -69.67m | 7.78bn | 219.00 | -- | 10.32 | -- | 24.24 | -2.91 | -2.91 | 13.51 | 29.44 | -- | -- | -- | 936,095.90 | -- | -- | -- | -- | 56.06 | -- | -21.72 | -- | -- | -- | 0.1296 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
| Swedencare AB (publ) | 2.34bn | 58.60m | 9.52bn | 486.00 | 162.52 | 1.32 | 25.85 | 4.07 | 0.3692 | 0.3692 | 14.73 | 45.40 | 0.2395 | 2.50 | 10.23 | 4,811,523.00 | 0.6002 | 1.38 | 0.6195 | 1.43 | 55.20 | 55.34 | 2.51 | 5.10 | 1.99 | 1.96 | 0.1871 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| AddLife AB | 9.69bn | 191.00m | 11.54bn | 2.30k | 62.46 | 2.41 | 10.29 | 1.19 | 1.57 | 1.57 | 79.48 | 40.69 | 0.7507 | 3.69 | 6.94 | 4,209,040.00 | 1.49 | 5.31 | 2.25 | 8.83 | 37.16 | 36.88 | 1.98 | 5.79 | 0.4541 | 1.66 | 0.5085 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| BioGaia AB | 1.30bn | 365.35m | 11.67bn | 210.00 | 33.17 | 5.97 | 29.88 | 9.00 | 3.62 | 3.62 | 12.84 | 20.11 | 0.5703 | 2.14 | 10.96 | 6,173,838.00 | 16.07 | 15.47 | 17.45 | 16.93 | 73.29 | 73.30 | 28.18 | 27.70 | 8.65 | -- | 0.0043 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| BioArctic AB | 615.99m | 229.25m | 14.51bn | 83.00 | 76.42 | 16.62 | 58.59 | 23.56 | 2.58 | 2.58 | 6.97 | 11.85 | 0.6026 | -- | -- | -- | 22.43 | 2.24 | 24.80 | 2.56 | 91.73 | 86.52 | 37.22 | 9.76 | -- | -- | 0.0047 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | -- | -- |
| Bonesupport Holding AB | 591.08m | 245.02m | 15.65bn | 110.00 | 64.01 | 28.92 | 62.01 | 26.49 | 3.72 | 3.72 | 9.04 | 8.24 | 1.11 | 0.7186 | 6.60 | 5,373,428.00 | 46.20 | -9.08 | 58.31 | -11.28 | 91.51 | 90.25 | 41.45 | -11.65 | 2.46 | -- | 0.0311 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Bavarian Nordic A/S | 11.05bn | 2.31bn | 18.21bn | 1.38k | 7.66 | 1.12 | 5.74 | 1.65 | 19.46 | 19.46 | 92.83 | 132.47 | 0.5281 | 1.92 | 6.10 | 5,121,349.00 | 11.03 | 1.21 | 13.62 | 1.48 | 65.18 | 53.72 | 20.89 | 4.06 | 1.35 | -- | 0.0139 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Vitrolife AB | 3.51bn | -3.85bn | 24.69bn | 1.08k | -- | 1.94 | -- | 7.03 | -28.44 | -28.44 | 25.94 | 93.96 | 0.1905 | 3.75 | 7.34 | 3,254,866.00 | -20.88 | -4.57 | -21.58 | -4.78 | 56.32 | 58.38 | -109.65 | -21.89 | 2.69 | -28.98 | 0.141 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Camurus AB | 1.72bn | 431.44m | 28.69bn | 213.00 | 66.42 | 18.55 | 64.40 | 16.71 | 7.49 | 7.49 | 30.11 | 26.84 | 1.07 | 1.17 | 7.29 | 8,060,329.00 | 26.85 | -1.13 | 33.67 | -1.41 | 92.87 | 90.05 | 25.13 | -1.63 | 4.13 | -- | 0.0162 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 7.55bn | 760.50m | 40.00bn | 2.82k | 60.32 | 6.28 | 32.90 | 5.30 | 2.09 | 2.09 | 20.90 | 20.10 | 0.7402 | 1.32 | 6.11 | 1,708,215.00 | 7.46 | 3.50 | 9.42 | 4.37 | 62.91 | 60.66 | 10.07 | 5.07 | 1.18 | 35.05 | 0.1468 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
Data as of Apr 18 2024. Currency figures normalised to Camurus AB's reporting currency: Swedish Krona SEK
18.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Nov 2023 | 2.49m | 4.32% |
| Didner & Gerge Fonder ABas of 31 Oct 2022 | 2.33m | 4.05% |
| Swedbank Robur Fonder ABas of 29 Feb 2024 | 1.69m | 2.94% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 758.04k | 1.32% |
| Lancelot Asset Management ABas of 31 Dec 2022 | 625.00k | 1.09% |
| SEB Investment Management ABas of 28 Mar 2024 | 621.99k | 1.08% |
| E. �hman J :or Fonder ABas of 31 Oct 2022 | 587.94k | 1.02% |
| Devon Equity Management Ltd.as of 31 Mar 2024 | 584.48k | 1.01% |
| AFA Sjukf�rs�kringsaktiebolag (Invt Mgmt)as of 31 Oct 2022 | 560.46k | 0.97% |
| Handelsbanken Fonder ABas of 31 Oct 2022 | 467.69k | 0.81% |
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
